Alkaptonuria – Leczenie

Alkaptonuria
Leczenie

Alkaptonuria (AKU) to rzadka choroba metaboliczna dziedziczona autosomalnie recesywnie, spowodowana niedoborem enzymu homogentyzyno-1,2-dioksygenazy, prowadząca do akumulacji kwasu homogentyzynowego (HGA). Przełomem w terapii AKU jest nitizynon, inhibitor 4-hydroksyfenylopirogronianu dioksygenazy, który w dawce 2 mg/dobę redukuje stężenie HGA w osoczu i moczu o ponad 95%, a dawka 10 mg/dobę wykazuje jeszcze silniejsze działanie. Badania kliniczne, w tym 4-letnie, randomizowane badanie SONIA 2, potwierdziły nie tylko redukcję HGA, ale także spowolnienie progresji ochronozy i poprawę wskaźnika nasilenia AKU (AKUSSI). Terapia nitizynonem jest zatwierdzona przez EMA dla pacjentów powyżej 16 roku życia, jednak wymaga ścisłego monitorowania hipertyrozynemii i stosowania diety niskobiałkowej, aby ograniczyć działania niepożądane, takie jak keratopatia rogówkowa czy toksyczność neurologiczna. Dodatkowo, dieta ograniczająca spożycie tyrozyny i fenyloalaniny (np. do 0,8-0,9 g/kg masy ciała w zależności od stężenia tyrozyny w surowicy) oraz suplementacja aminokwasów wolnych od tych aminokwasów są stosowane w celu kontroli poziomu tyrozyny.

Leczenie alkaptonurii

Leczenie nitizononem
Leczenie dietetyczne
Suplementacja witaminy C
Leczenie objawowe
Leczenie chirurgiczne
Nowe kierunki terapeutyczne

Profilaktyka i zapobieganie powikłaniom
Podsumowanie efektywności leczenia

Ograniczenia i wyzwania w leczeniu
Znaczenie podejścia multidyscyplinarnego
Kolejne rozdziały

Leczenie alkaptonurii

Alkaptonuria (AKU) jest rzadką chorobą metaboliczną dziedziczoną autosomalnie recesywnie, wywołaną niedoborem enzymu homogentyzyno-1,2-dioksygenazy. Mimo że jest jedną z pierwszych odkrytych chorób genetycznych podlegających prawu Mendla, przez długi czas nie istniała skuteczna terapia przyczynowa tej choroby. Dopiero w ostatnich latach pojawiły się nowe możliwości terapeutyczne, które mogą istotnie wpłynąć na przebieg kliniczny tego schorzenia.¹²

Leczenie nitizononem

Przełomem w terapii alkaptonurii okazał się nitizynon – lek hamujący aktywność enzymu 4-hydroksyfenylopirogronianu dioksygenazy, który uczestniczy w powstawaniu kwasu homogentyzynowego (HGA). Nitizynon skutecznie blokuje konwersję tyrozyny do kwasu homogentyzynowego, zmniejszając jego gromadzenie w tkankach.¹²

Badania kliniczne wykazały, że nitizynon w dawce 2 mg/dobę powoduje redukcję stężenia HGA w osoczu i moczu o ponad 95%, natomiast dawka 10 mg/dobę wykazuje jeszcze silniejsze działanie hamujące.¹² W 2020 roku, na podstawie wyników badań klinicznych programu DevelopAKUre, Europejska Agencja Leków (EMA) zatwierdziła nitizynon jako pierwszy lek modyfikujący przebieg alkaptonurii u dorosłych pacjentów.¹²

Najważniejsze badania kliniczne obejmowały:

Badanie SONIA 1 (Suitability of Nitisinone in AKU 1) – badanie ustalające zakres dawkowania, w którym wykazano, że dawka 8 mg nitizynonu była skuteczna w obniżaniu krążącego HGA u pacjentów z alkaptonurią.¹
Badanie SONIA 2 – 4-letnie randomizowane wieloośrodkowe międzynarodowe badanie kliniczne, które nie tylko potwierdziło zmniejszenie stężenia HGA w surowicy i moczu, ale również wykazało zmniejszenie ochronozy oczu i spowolnienie progresji klinicznej choroby ocenianej za pomocą wskaźnika nasilenia AKU (AKUSSI).¹²

Należy jednak zaznaczyć, że stosowanie nitizynonu wiąże się z wystąpieniem hipertyrozynemii – podwyższonego stężenia tyrozyny we krwi, co może prowadzić do działań niepożądanych, takich jak: keratopatia rogówkowa, toksyczność skórna, problemy z opóźnieniem rozwoju neuronalnego u dzieci oraz zaburzenia szerszego metabolizmu.¹² Z tego powodu, pacjenci przyjmujący nitizynon muszą przestrzegać diety o ograniczonej zawartości białka i ściśle monitorować poziom tyrozyny poprzez regularne badania kontrolne.

Ze względu na potencjalne działania niepożądane nitizynonu w Europie jest on obecnie przepisywany wyłącznie osobom w wieku 16 lat i starszym.¹ Trwają badania nad optymalizacją dawkowania nitizynonu, aby osiągnąć maksymalną skuteczność przy minimalizacji działań niepożądanych – niektóre badania sugerują, że już dawka 0,22 mg dziennie zmniejszy wydalanie kwasu homogentyzynowego z moczem o 90%.¹

Leczenie dietetyczne

Dieta niskoproteinowa może zmniejszyć obciążenie tyrozyną i fenyloalaniną, co potencjalnie prowadzi do zmniejszenia produkcji kwasu homogentyzynowego.¹² Ograniczenia dietetyczne obejmują:

Ograniczenie spożycia pokarmów bogatych w tyrozynę i fenyloalaninę, takich jak mięso, ryby, jaja, sery oraz żywność zawierająca sztuczne słodziki, np. aspartam.¹²
W Brytyjskim Narodowym Centrum Alkaptonurii przyjmuje się pragmatyczne podejście do diety w zależności od stężenia tyrozyny w surowicy (sTYR): przy wartościach sTYR między 501-700 μmol/L spożycie białka jest ograniczone do 0,9 g/kg masy ciała, przy wartościach 701-900 μmol/L do 0,8 g/kg masy ciała, a przy wartościach powyżej 900 μmol/L stosuje się również suplementy aminokwasów wolnych od fenyloalaniny/tyrozyny.¹

Chociaż dieta niskoproteinowa może być pomocna, wielu pacjentów ma trudności z przestrzeganiem tych ograniczeń.¹ Ponadto skuteczność takiego podejścia w zapobieganiu długoterminowym powikłaniom nie została jednoznacznie udowodniona.¹

Suplementacja witaminy C

Kwas askorbinowy (witamina C) w dużych dawkach (do 1 g dziennie) był tradycyjnie zalecany dla starszych dzieci i dorosłych z alkaptonurią.¹² Witamina C, ze względu na swoje właściwości antyoksydacyjne, spowalnia proces konwersji kwasu homogentyzynowego do materiału polimerycznego, który odkłada się w tkankach chrzęstnych.¹

Należy jednak zaznaczyć, że długotrwałe stosowanie witaminy C może czasami zwiększać ryzyko powstawania kamieni nerkowych i generalnie okazało się nieskuteczne w długoterminowym leczeniu tego schorzenia.¹² Ponadto witamina C nie wpływa na wydalanie kwasu homogentyzynowego z moczem.¹

Leczenie objawowe

Ze względu na postępujący charakter choroby i rozwój powikłań, istotnym elementem terapii alkaptonurii jest leczenie objawowe:¹²

Leki przeciwbólowe i przeciwzapalne, takie jak paracetamol, niesteroidowe leki przeciwzapalne (NLPZ) i w ciężkich przypadkach leki narkotyczne, pomagają łagodzić ból stawów.¹²
Fizjoterapia i terapia zajęciowa mogą pomóc w utrzymaniu siły mięśniowej, elastyczności i zakresu ruchu stawów.¹²
Regularna, łagodna aktywność fizyczna pomaga budować mięśnie i wzmacniać stawy, przy czym należy unikać ćwiczeń obciążających stawy.¹²
W leczeniu objawów ocznych stosuje się soczewki kontaktowe w przypadku astygmatyzmu oraz standardowe leki przeciwjaskrowe, choć mogą one nie być skuteczne ze względu na odmienną patogenezę powikłań w alkaptonurii.¹

Leczenie chirurgiczne

W zaawansowanym stadium choroby może być konieczne leczenie chirurgiczne:¹²

Artroskopia okazała się skuteczna w łagodzeniu bólu stawów i poprawie mobilności w przypadkach artropatii ochronotycznej.¹
Wymiana stawów (kolanowych, biodrowych, barkowych) jest często konieczna, gdy artropatia ochronotyczna znacznie postępuje – około 50% osób z alkaptonurią przechodzi wymianę stawu do 55 roku życia.¹²
Interwencja chirurgiczna w przypadku kamieni prostaty i nerek.¹
Wymiana zastawki aortalnej jest wskazana w przypadku zwapnienia i zwężenia aorty.¹

Nowe kierunki terapeutyczne

Trwają badania nad nowymi podejściami terapeutycznymi, które mogą zapewnić skuteczniejsze i bezpieczniejsze metody leczenia alkaptonurii:¹²

Techniki manipulacji genetycznej, takie jak zmodyfikowany CRISPR/Cas9 (FokI-dCas9), techniki homologii końcowego łączenia (EJHTs) i indukowane pluripotencjalne komórki macierzyste (iPSCs) mogą być w przyszłości korzystne w leczeniu alkaptonurii.¹
Terapia genowa lub enzymatyczna, która bezpośrednio zastępuje brakujący enzym HGD, jest badana jako potencjalne lekarstwo na alkaptonurię, choć badania napotykają trudności w jej wdrożeniu.¹²
Badania z wykorzystaniem sztucznej inteligencji do projektowania leków doprowadziły do opracowania nowych związków hamujących 4-hydroksyfenylopirogronian dioksygenazę, które potencjalnie mogą mieć mniejszą toksyczność niż nitizynon.¹²³
Inne przeciwutleniacze, takie jak N-acetylocysteina i witamina E, są badane jako potencjalne terapie zapobiegające uszkodzeniom chrząstki stawowej.¹²

Profilaktyka i zapobieganie powikłaniom

Wczesne rozpoznanie alkaptonurii jest kluczowe dla skutecznej profilaktyki powikłań. Ciemne plamy na pieluszkach niemowląt powinny alertować lekarza o możliwości występowania alkaptonurii.¹

Istnieje możliwość zastosowania nitizynonu w niskich dawkach jako leczenia zapobiegawczego u młodszych pacjentów, aby uniknąć rozwinięcia powikłań związanych z AKU. Badania sugerują, że wczesne rozpoczęcie leczenia może opóźnić powikłania i zapobiec konieczności wymiany stawów lub naprawy zastawek serca.¹

Ponadto, regularne monitorowanie i kontrole lekarskie są niezbędne do obserwacji progresji choroby i dostosowania strategii leczenia. Może to obejmować częste wizyty u świadczeniodawców opieki zdrowotnej, w tym doradców genetycznych, reumatologów i chirurgów ortopedów, aby uwzględnić specyficzne aspekty schorzenia.¹²

Podsumowanie efektywności leczenia

Terapia nitizononem stanowi przełom w leczeniu alkaptonurii – jest to pierwszy lek modyfikujący przebieg choroby. Badania wykazały, że już po 12 miesiącach leczenia nitizononem stężenie kwasu homogentyzynowego (HGA) zmniejszyło się o 99,7%.¹

Brytyjska Narodowa Służba ds. Alkaptonurii (gdzie kierowani są wszyscy pacjenci z Wielkiej Brytanii) odnotowała, że u wszystkich pacjentów, którzy byli leczeni przez ponad rok, nastąpiła poprawa we wszystkich domenach skali jakości życia SF36, z wyjątkiem energii/zmęczenia.¹

Należy jednak pamiętać, że chociaż nitizynon jest bezpieczną i skuteczną terapią dla AKU, może on jedynie leczyć, a nie wyleczyć chorobę.¹ Osoby z alkaptonurią przy odpowiednim leczeniu mogą prowadzić normalne życie, a oczekiwana długość życia jest dość typowa. Ponadto, odpowiednie leczenie objawów może pomóc opóźnić powikłania związane z tym schorzeniem.¹

Ograniczenia i wyzwania w leczeniu

Pomimo obiecujących wyników terapii nitizononem, istnieje kilka wyzwań i ograniczeń związanych z leczeniem alkaptonurii:¹²

Leczenie hipertyrozynemii wywołanej nitizononem jest trudne u dorosłych ze względu na znacznie ograniczoną dietę, co wpływa na jakość życia pacjentów.
Optymalne stężenie tyrozyny w surowicy nie jest osiągalne bez suplementów aminokwasów wolnych od fenyloalaniny/tyrozyny.
Nie jest jasne, czy konieczne jest zmniejszenie stężenia kwasu homogentyzynowego w moczu do wartości obserwowanych u osób zdrowych, oraz jakie inne czynniki mogą determinować stopień pozostałych szkód spowodowanych przez nieznacznie podwyższone stężenia HGA.¹
Ze względu na potencjalne efekty uboczne nitizynonu, w Stanach Zjednoczonych FDA nie zatwierdziła jeszcze jego stosowania w leczeniu alkaptonurii.¹

Znaczenie podejścia multidyscyplinarnego

Skuteczne leczenie alkaptonurii wymaga podejścia multidyscyplinarnego, obejmującego:¹²

Dietetyka – aby opracować i monitorować dietę z ograniczeniem białka
Fizjoterapia – kluczowa w utrzymaniu mobilności i zmniejszeniu bólu
Reumatologia – do monitorowania i leczenia objawów stawowych
Kardiologia – do oceny i leczenia powikłań sercowo-naczyniowych
Nefrologia – do monitorowania funkcji nerek i leczenia kamicy nerkowej
Ortopedia – w przypadku konieczności wymiany stawów
Okulistyka – do monitorowania i leczenia objawów ocznych
Psychologia – grupy wsparcia i usługi doradztwa mogą zapewnić platformę dla osób do dzielenia się doświadczeniami, szukania porad i otrzymywania wsparcia emocjonalnego od innych osób stojących przed podobnymi wyzwaniami¹

Doświadczenia z rozwoju terapii alkaptonurii pokazują, że współpraca między klinicystami, naukowcami zajmującymi się naukami podstawowymi, organizacjami pacjentów i potencjalnymi fundatorami może przynieść szybkie postępy w opracowywaniu skutecznych metod leczenia rzadkich chorób.¹²

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Alkaptonuria | Treatment & Management | Point of Care
https://www.statpearls.com/point-of-care/17363
Despite being one of the first discovered genetic disorders that are supposed to follow Mendelian law, to date, there is no effective treatment for AKU. Therefore, the management of alkaptonuria remains palliative, which includes pain control, physiotherapy, and joints surgery. Additionally, the main focus of the treatment is to reduce the deposition of HGA. […] Commonly recommended therapy involves ascorbic acid, which known as vitamin C due to the effect on reducing the conversion of homogentisic acid to benzoquinone acetic acid by oxidation. However, it does not affect the urinary excretion of homogentisic acid. […] A low protein diet can reduce tyrosine load and reduce the severity of the disease, but compliance with dietary requirements is not easy. Efficacy is unproven. […] Many studies have suggested that nitisinone, a triketone herbicide has a significant impact on the treatment of AKU. The enzyme 4-hydroxyphenylpyrvute dioxygenase believed to play a role in converting the hydroxyphenylpyruvate to HGA. Therefore, nitisinone inhibits the conversion of tyrosine to homogentisic acid. Also, nitisinone therapy(2 mg/day )has shown to produce a reduction in urinary and plasma HGA larger than 95% hence, increase the levels of tyrosine in the body. Other serious side effects associated with raised plasma tyrosine levels rather than corneal irritation include leukopenia, thrombocytopenia, and porphyria.
#1 Development of an effective therapy for alkaptonuria â Lessons for osteoarthritis
https://www.degruyterbrill.com/document/doi/10.2478/rir-2021-0011/html?lang=en&srsltid=AfmBOoqM__gLQVXTUrDd2aiSdLeLwegMe0s2sF3PtxQhqqZT-7_jdCLJ
Osteoarthritis (OA) is one of the major causes of disability and pain worldwide, yet despite a massive international research effort, no effective disease-modifying drugs have been identified to date. […] Until recently, there was no effective therapy for AKU, but preclinical studies demonstrated that upstream inhibition of tyrosine metabolism by nitisinone, a drug previously used in hereditary tyrosinaemia 1 (HT1), completely prevented ochronosis in AKU mice. This was followed by successful clinical trials which have resulted in nitisinone being approved for therapy of AKU by the European Medicines Agency, making AKU the only cause of OA for which there is an effective therapy to date. […] Nitisinone was effective at lowering HGA in AKU patients, but an early clinical trial at the National Institute of Health, USA, failed to demonstrate an improvement in musculoskeletal function, probably because of the slow progression of the disease, the type of assessment undertaken, and the limited number of patients in the trial. However, in preclinical studies, we were able to demonstrate that nitisinone was completely effective at preventing ochronosis in the AKU mouse, and when administered mid-life, it was shown to arrest, but not reverse, further ochronosis.
#1 Alkaptonuria – Wikipedia
https://en.wikipedia.org/wiki/Alkaptonuria
In 2012 the AKU Society formed a consortium called DevelopAKUre to prove that nitisinone, a drug already approved for treating another rare disease, hereditary tyrosinaemia type-1, could be repurposed to treat AKU. […] The DevelopAKUre trials concluded in 2019 and successfully illustrated that nitisinone lowered levels of homogentisic acid (HGA), the acid that causes the damage in AKU, by 99% which effectively halts the progression of the disease. In 2020, the European Medicines Agency and the European Commission approved the use of nitisinone for treating AKU making the treatment available to patients across the Europe and the UK. […] Nitisinone has revolutionised the treatment of AKU, however it can lead to a condition known as hypertyrosinaemia caused by elevated levels of the amino acid tyrosine. Hypertyrosinaemia can lead to serious symptoms including corneal keratopathy, dermal toxicity, neurodevelopment delay issues in children, and alterations of wider metabolism. There is currently no effective treatment for hypertyrosinaemia other than limiting protein intake. Due to the potential side-effects of nitisinone treatment it is currently only prescribed to children aged 16 and above in Europe and patients will then have to follow a protein restricted diet and closely manage their tyrosine levels through frequent monitoring.
#1 Development of an effective therapy for alkaptonuria â Lessons for osteoarthritis
https://www.degruyterbrill.com/document/doi/10.2478/rir-2021-0011/html?lang=en&srsltid=AfmBOoqM__gLQVXTUrDd2aiSdLeLwegMe0s2sF3PtxQhqqZT-7_jdCLJ
Following these findings, we received funding from the European Commission as part of the Framework Programme 7 (EUFP7) for the DevelopAKUre Programme to undertake clinical trials on nitisinone. In the dose-ranging study of suitability of nitisinone in AKU 1 (SONIA 1), 8 mg of nitisinone was effective at lowering circulating HGA in AKU patients. This was followed by a 4-year randomized multicentre international clinical study, called suitability of nitisinone in AKU 2 (SONIA 2), which not only confirmed the decrease in serum and urine HGA levels but also demonstrated a decrease in eye ochronosis and a slowing down of clinical disease progression as assessed by AKU severity score index (AKUSSI), a validated AKU severity score index. These studies have contributed to the approval of nitisinone as the first disease-modifying treatment of adult AKU by the European Medicines Agency and the European Commission. […] Although nitisinone is a safe and effective therapy for AKU, it can only treat and not cure the disease.
#1 Preventive use of nitisinone in alkaptonuria | Orphanet Journal of Rare Diseases | Full Text
https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01977-0
Alkaptonuria (AKU, OMIM 203500) is a rare congenital disorder caused by a deficiency of the enzyme homogentisate-1,2,-dioxygenase. Landmark intervention studies with nitisinone 10 mg daily, suppressing an upstream enzyme activity, demonstrated its beneficial effects in AKU patients with established complications, which usually start to develop in the fourth decade. Lower dose of nitisinone in the range of 0.22 mg daily will already reduce urinary homogentisic acid (uHGA) excretion by 90%, which may prevent AKU-related complications earlier in the course of the disease while limiting the possibility of side-effects related to the increase of plasma tyrosine levels caused by nitisinone. […] Nitisinone (2-(2-nitro-4-(trifluoromethyl)benzoyl) cyclohexane-1,3-dione) is a drug which has been used for over 20 years for the treatment of children with Tyrosinaemia type I (TT1). Based on this action, it can be expected that treatment of AKU patients with nitisinone may therefore reduce the consequences of the disorder, especially the joint destruction and the ochronosis of for instance the eye which develops with long-standing disease. Indeed, several recent studies have shown that chronic treatment with 10 mg nitisinone daily for a period up to 4 years did reduce the rate of progression of AKU-related symptoms and arrest or even reverse ochronotic pigmentation.
#1 Alkaptonuria: Causes, Symptoms, and Treatment Methods | DocHospitals
https://dochospitals.com/en/alkaptonuria-atc1324/
Although there is no definitive treatment method for alkaptonuria, treatment is usually aimed at reducing the patient’s symptoms. Medications and changes in the patient’s lifestyle aim to reduce the symptoms of the disease. […] In alkaptonuria, drugs with the active substance nitisinone are preferred medically. There are ongoing studies showing that nitisinone reduces the level of homogentisic acid in the body. […] For people with involvement of the joints and spine, relief is provided with painkillers. In advanced cases, joint replacement can be performed with surgical operations. […] Physiotherapy support to strengthen muscles and joints improves the patient’s quality of life. […] Regular light exercise helps to reduce the pain of the disease. Activities that reduce stress levels such as yoga, pilates, cycling and walking can be preferred. […] Surgery may be necessary in patients with involvement of heart valves or heart vessels. […] The use of vitamin C slows down calcification in some patients and reduces the dark color of urine. […] Reduce consumption of foods rich in tyrosine and phenylalanine, such as milk, meat and eggs.
#1 Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria | Scientific Reports
https://www.nature.com/articles/s41598-022-20424-z
Protein intake is reduced to 0.9 and 0.8 g/kg body weight for sTYR values between 501-700, and 701-900 mol/L respectively, whereas in those with values greater than 900 mol/L, additional PHE/TYR free amino acid supplements are also employed. […] The decrease in conversion of PHE to TYR during NIT-induced tyrosinaemia seems to be an adaptive response to minimise TYR formation. […] A better understanding of the adaptive response to NIT therapy may possibly translate into a tool to predict keratopathy in the future. […] The contributions of dietary protein intake and the magnitude of rise in circulating NIT seem to be less influential than decreased conversion of HPPA to HPLA in determining the degree of tyrosinaemia during NIT treatment in SONIA 2.
#1 Alkaptonuria Information | Mount Sinai – New York
https://www.mountsinai.org/health-library/diseases-conditions/alkaptonuria
Management of alkaptonuria has traditionally been focused on controlling symptoms. Eating a low protein diet may be helpful, but many people find this restriction difficult. Medicines, such as NSAIDs and physical therapy may help relieve joint pain. […] Clinical trials are underway for other drugs to treat this condition and to assess whether the drug nitisinone provides long-term help with this illness.
#1 Alkaptonuria (Black Urine Disease) Treatment & Management: Medical Care, Surgical Care, Consultations
https://emedicine.medscape.com/article/941530-treatment
In infancy, a history of dark-stained diapers should alert the physician to alkaptonuria. […] Medical therapy is used to ameliorate the rate of pigment deposition. This minimizes articular and cardiovascular complications in later life. […] Reduction of phenylalanine and tyrosine has reportedly reduced homogentisic acid excretion. Whether a mild dietary restriction from early in life would avoid or minimize later complications is not known, but such an approach is reasonable. […] Vitamin C, as much as 1 g/d, is recommended for older children and adults. The mild antioxidant nature of ascorbic acid helps to retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. […] More recently, use of nitisinone, an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase, which mediates formation of homogentisic acid, has been reported. Urinary homogentisate excretion was markedly reduced, and safety of prolonged use is no longer an open question.
#1 Alkaptonuria: Causes, Symptoms and Diagnosis
https://www.healthline.com/health/alkaptonuria
Alkaptonuria is a lifelong condition, but there are many ways to help manage your symptoms. […] Theres no specific treatment for alkaptonuria. Instead, treatment is focused largely on managing symptoms. […] There are many therapies that have been tried, but unfortunately they havent been proven to be effective, and may be harmful or unhelpful in the long term. […] However, The National Institutes of Health warns that long-term use of vitamin C can sometimes increase the production of kidney stones and has generally proven ineffective for long-term treatment of this condition. […] Other treatments for alkaptonuria are focused on preventing and relieving possible complications, such as arthritis, heart disease, and kidney stones. […] For example, your doctor may prescribe anti-inflammatory medications or narcotics for joint pain. Physical and occupational therapy may help you maintain flexibility and strength in your muscles and joints.
#1 Alkaptonuria: Causes, Symptoms, Diagnosis, and Treatment Options Explained | OnlyMyHealth
https://www.onlymyhealth.com/alkaptonuria-causes-symptoms-diagnosis-treatment-12977827239
While there is no cure for alkaptonuria, treatment can help manage symptoms and prevent complications. Some effective strategies include: […] Medication: Nitisinone, a drug that reduces homogentisic acid production, may help slow disease progression. […] Pain management: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and physical therapy can help relieve joint pain. […] Lifestyle changes: A low-protein diet may help reduce the production of homogentisic acid. […] Surgical interventions: In severe cases, joint replacement surgery may be necessary. […] Regular monitoring: Routine check-ups can help manage cardiovascular and kidney-related complications. […] Alkaptonuria is a lifelong condition that requires careful management to prevent complications and maintain quality of life. Early diagnosis and appropriate interventions, such as medication, lifestyle modifications, and regular medical check-ups, can help individuals manage the symptoms effectively.
#1 How Is Alkaptonuria Managed?
https://www.icliniq.com/articles/kidney-and-urologic-diseases/alkaptonuria
Alkaptonuria is a long-term and chronic condition, and there is no particular treatment for the condition. However, certain medications and treatment choices help to cope with the symptoms. […] If alkaptonuria is diagnosed early in childhood, it is possible to slow down its progression by restricting protein intake. Reduced protein intake can reduce tyrosine and phenylalanine levels in the body. This reduced protein intake can also lower the side effects of the medications taken during treatment. […] Exercises help improve some of the symptoms of alkaptonuria, such as joint stiffness and pain. Regular and routine exercises help build muscles and strengthen the joints. But you have to ensure that the exercises do not strain your joints. If you feel there is additional strain, avoid such exercises that stress the joints.
#1 Ocular Manifestations of Alkaptonuria | Treatment & Management | Point of Care
https://www.statpearls.com/point-of-care/141578
Ophthalmologic management includes contact lenses for astigmatism and trabeculectomy for glaucoma. […] For glaucoma, a trial of standard medication therapy (e.g., timolol, carbonic anhydrase inhibitor, and latanoprost topical eye drops) can be utilized. Still, it may not prove effective due to the different pathogenesis of the complication. […] Further research would be beneficial to clarify disease and complication relationships and management.
#1 Alkaptonuria: Causes, Symptoms and Diagnosis
https://www.healthline.com/health/alkaptonuria
At some point in your life, you might need surgery. […] The World Institutes of Health reports adults can experience a buildup of homogentisic acid in cartilage, resulting in arthritis. As a result those with alkaptonuria may need a shoulder, knee, or hip replacement. […] You may also require surgery to replace your aortic or mitral heart valves, if they stop working properly. In some cases, you may need surgery or other therapies to treat chronic kidney or prostate stones.
#1 Ochronosis and Alkaptonuria Treatment & Management: Medical Care, Surgical Care, Consultations
https://emedicine.medscape.com/article/1104184-treatment
Arthroscopy has been found to be effective in alleviating joint pain and improving mobility in cases of ochronotic arthropathy. […] Knee, hip, shoulder, and other joint replacements may be needed if ochronotic arthropathy progresses substantially. Surgical intervention for prostate and renal stones may also be necessary. Aortic valve replacement is indicated in the case of aortic calcification and stenosis. […] Surgical replacement of cardiac valves may be necessary in cases of ochronosis.
#1 Alkaptonuria – ThinkGenetic Foundation
https://thinkgenetic.org/diseases/alkaptonuria/
About 50% of people with Alkaptonuria have a joint replacement by the age of 55 to treat arthritis. Joint replacement is an option for anyone who has been diagnosed with Alkaptonuria, and it is primarily considered to reduce pain. […] There is clinical research currently being conducted for Alkaptonuria as of May 2019. Most of the current research is focused on treating Alkaptonuria with a drug called NTBC. This drug has been shown to reduce the amount of HGA excreted in the urine, and clinical trials are currently looking at possible long term effects of the drug.
#1 Control of Alkaptonuria With Nitisinone and Gene Therapy: A Systematic Review by Martin Nelwan :: SSRN
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3771956
No adequate treatment is available for AKU at present. […] Candidate drugs of AKU are nitisinone and genetic manipulation techniques. […] Research results on the use of nitisinone on AKU have shown remarkable improvements. […] In the future, genetic manipulation techniques may be beneficial for treating AKU. These techniques are such as modified CRISPR/Cas9 (FokI-dCas9), End-Joining Homology Techniques (EJHTs) and induced Pluripotent Stem Cells (iPSCs).
#1 Ocular Manifestations of Alkaptonuria | Treatment & Management | Point of Care
https://www.statpearls.com/point-of-care/141578
Gene or enzyme replacement therapy that directly replaces the missing HGD enzyme is being investigated as a potential cure for alkaptonuria. […] While ideal, in theory, studies focusing on this therapy have reported difficulties in its implementation. Enzyme replacement therapy requires precise tissue localization and can accumulate reactive, toxic intermediates of tyrosine metabolism in the blood and tissues. […] In addition to treatment targeting biochemical pathways, supportive management that addresses the most noticeable and distressing symptoms should also be discussed. Physical and occupational therapy can help maintain muscle strength, flexibility, and range of motion, while anti-inflammatory analgesics can be used for arthralgias. […] In more advanced degenerative arthritis, joint arthroplasty may be indicated.
#1 Redefining a new frontier in alkaptonuria therapy with AI-driven drug candidate design via in-silico innovation
https://www.degruyter.com/document/doi/10.1515/znc-2024-0075/html?lang=en
A rare metabolic condition called alkaptonuria (AKU) is caused by a decrease in homogentisate 1,2 dioxygenase (HGO) activity due to a mutation in homogentisate dioxygenase (HGD) gene. […] Employing the use of deep learning artificial intelligence (AI) drug design, this study aims to alleviate the current toxicity of the AKU drugs currently in use, particularly nitisinone, by utilizing the natural flavanol kaempferol molecule as a 4-hydroxyphenylpyruvate dioxygenase inhibitor. […] The toxicity assessment research of AIK demonstrates that it is not only safer to use than other treatments, but also more efficient. […] Alkaptonuria does currently not have a known treatment; nonetheless, it is handled with physiotherapy, analgesics, and joint replacement surgery. […] In more recent years, nitisinone has been used to prevent the buildup of homogentisic acid in alkaptonuria (AKU), and there is evidence to support its effectiveness as a disease-modifying substance.
#1 Ochronosis and Alkaptonuria Treatment & Management: Medical Care, Surgical Care, Consultations
https://emedicine.medscape.com/article/1104184-treatment
Ranganath et al have shown that nitisinone 2 mg daily and 10 mg daily are beneficial in patients with alkaptonuria, with 10 mg displaying a greater decrease in HGA. The authors note that a diet lower in protein would likely improve safety with the higher dose. Nitisinone 10 mg was approved by the European Medicines Agency for adults with alkaptonuria in 2020. […] Nitisinone is approved in the United States for the treatment of children with tyrosinemia type I. It acts by inhibiting the enzyme 4-hydroxyphenyl pyruvic acid and therefore can decrease formation of HGA. […] Vitamin E and N-acetyl cysteine have been examined as novel potential therapies to prevent damage to articular cartilage. […] Ochronotic arthropathy is treated with physiotherapy, analgesia, rest, and prosthetic joint replacement when necessary.
#1 Preventive use of nitisinone in alkaptonuria | Orphanet Journal of Rare Diseases | Full Text
https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01977-0
The proven efficacy of nitisinone to mitigate or reverse the complications associated with AKU holds promise for early preventive therapy with this medication. There may be a large window of opportunity to start early treatment with nitisinone to reduce HGA levels in order to prevent such damage, and an observational study to assess the progression of AKU-related complications in children, the SOFIA-Paediatric study, is ongoing. […] Early low-dose preventive treatment may postpone complications and prevent the necessity for joint replacements or cardiac valve repair or replacement, while in the same time there may be a lower risk of drug-related side-effects. […] Important questions such as the optimal age at start of treatment, the desired dose of nitisinone and the need of a diet need to be addressed in our conversations with patients. When started early in the course of the disease, for instance in the third decade or even earlier, treatment with nitisinone perhaps at even lower doses than used in the intervention studies may be able to prevent the development of the long-term consequences as a result of its HGA-reducing properties.
#1 Alkaptonuria Disease: Symptoms, Causes and Treatment
https://tap.health/how-to-diagnose-alkaptonuria-urine-analysis-and-genetic-testing/
Currently, there is no cure for Alkaptonuria. However, various treatment options aim to alleviate symptoms and improve the quality of life for individuals with this condition. […] The management of joint pain and stiffness often involves a multidisciplinary approach. Healthcare professionals may prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) and recommend physical therapy to help patients alleviate discomfort and maintain joint mobility. In severe cases, joint replacement surgery may be necessary to restore function and relieve pain. […] Additionally, diet modifications may be suggested to minimize the intake of tyrosine and phenylalanine, which are precursors of HGA. To carefully balance dietary restrictions, one must ensure adequate nutrient intake. […] Furthermore, individuals with Alkaptonuria may benefit from regular monitoring and follow-up care to track the progression of the disease and adjust treatment strategies accordingly. This may involve frequent visits to healthcare providers, including genetic counselors, rheumatologists, and orthopedic surgeons, to address specific aspects of the condition.
#1
https://www.liverpool.ac.uk/health-and-life-sciences/research/impact/alkaptonuria/
Researchers at the University of Liverpool developed the first effective pharmacological treatment option for the disease which transforms management and experience of the disease. Young people with alkaptonuria can now expect to live free of its debilitating symptoms whilst existing older patients are seeing symptoms arrested and some reversed. […] During a ten-year period (2009-2019), the Liverpool team worked with nitisinone, eventually proving its efficacy as a therapy for alkaptonuria, through completing an observational study and clinical trials of the therapy. Findings included that at 12 months, homogentisic acid (HGA), the cause of alkaptonuria, was decreased by 99.7%. […] Based on Liverpools trial results, pharmaceutical company Swedish Orphan Biovitrum applied to the European Medicine Agency (EMA) to license the treatment, as Orfadin. EMA granted the license with the EU market size estimated as 2,275 patients, with 30-50 new patients identified each year.
#1
https://www.liverpool.ac.uk/health-and-life-sciences/research/impact/alkaptonuria/
The NHS England Highly Specialised Service for alkaptonuria patients, the National Alkaptonuria Service (where all UK patients are referred) found that of all patients who had been seen for over a year, improvements were present in all domains of the SF36 quality of life scale except energy/fatigue.
#1 How Is Alkaptonuria Managed?
https://www.icliniq.com/articles/kidney-and-urologic-diseases/alkaptonuria
Nitisinone is not approved for alkaptonuria, but currently, Nitisinone is recommended to treat this condition as it is known to reduce the levels of homogentisic acid in the body. At present, this is just an experimental treatment; the evidence of its effectiveness is still underway, and so far, there have been promising results from this treatment. […] In some instances of alkaptonuria, surgery can be suggested when the joints are damaged and require replacement or when heart valves or blood vessels are hardened. Some of the commonly preferred surgical procedures include hip replacement, knee replacement, and aortic valve replacement. […] Being diagnosed with chronic conditions like alkaptonuria can be emotionally stressful, but anxiety and depression can worsen the symptoms. So getting a doctors help is very important for mental health. […] Certain symptoms can considerably affect the quality of life. However, people with alkaptonuria can lead a normal life, and life expectancy is fairly normal. In addition, taking appropriate treatment for their symptoms can help delay the complications of the conditions.
#1 Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria | Scientific Reports
https://www.nature.com/articles/s41598-022-20424-z
Nitisinone (NIT) is approved by the European Medicines Agency as the first disease-modifying therapy for AKU. […] It decreases HGA by inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) and consequently ameliorates AKU. […] However, inhibition of HPPD also leads to accumulation of metabolites proximal to this inhibition, including TYR leading to severe tyrosinaemia which can cause unwanted effects such as corneal keratopathy, and, as more recently reported, vitiligo and cataract formation. […] Management of NIT-induced tyrosinaemia is challenging in adults due to the severely restricted diet needed affecting patients’ quality of life and optimal sTYR not being achievable without PHE/TYR-free amino acid supplements. […] In the United Kingdom National Alkaptonuria Centre, sTYR intervals are used pragmatically.
#1 Preventive use of nitisinone in alkaptonuria | Orphanet Journal of Rare Diseases | Full Text
https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01977-0
Thus, treatment with low dose nitisinone may be a game changer in the prevention of AKU-related complications, and allow an individual approach in young AKU patients. Future studies are needed to address whether it is mandatory to reduce urinary HGA concentrations to those in normal individuals, and which other factors may determine the degree of residual harm caused by slightly elevated HGA concentrations.
#1 Redefining a new frontier in alkaptonuria therapy with AI-driven drug candidate design via in-silico innovation
https://www.degruyter.com/document/doi/10.1515/znc-2024-0075/html?lang=en
However, because nitisinone use has resulted in acquired tyrosinosis, increased liver transaminases, and corneal crystals, the FDA has not approved its use to treat alkaptonuria. […] This study utilized the natural flavonol kaempferol as a 4-hydroxyphenylpyruvate dioxygenase inhibitor to address the toxicity issues associated with the AKU medication nitisinone. […] Therefore, it is important to optimize its therapeutic potential for a more effective treatment of alkaptonuria. […] Consequently, for the treatment of the patients, a drug designed specifically for alkaptonuria with few adverse effects is a dire need. […] The AI technology employed with kaempferol developed three effective de novo drug compounds that were effective against the 4-hydroxyphenylpyruvate dioxygenase enzyme.
#1 Alkaptonuria: Symptoms, Causes, Treatment
https://www.medicoverhospitals.in/diseases/alkaptonuria/
While there is currently no cure for alkaptonuria, various treatments can help manage the symptoms and prevent complications. […] A diet low in phenylalanine and tyrosine may help reduce the levels of homogentisic acid in the body. Foods to avoid include high-protein foods such as meat, fish, eggs, and cheese and foods containing artificial sweeteners like aspartame. […] This medication inhibits the enzyme responsible for the production of homogentisic acid. By reducing the levels of homogentisic acid, nitisinone can help alleviate symptoms and prevent complications. […] In severe cases, surgical interventions may be necessary: For individuals with significant joint damage, joint replacement surgery can improve mobility and reduce pain. […] Managing alkaptonuria requires a comprehensive, multidisciplinary approach involving diet, medication, physical therapy, and regular monitoring by healthcare professionals.
#1 Alkaptonuria: Symptoms, Causes, Treatment
https://www.medicoverhospitals.in/diseases/alkaptonuria/
Routine check-ups with healthcare providers are essential to monitor the progression of the disease and adjust treatment plans as needed. […] Physical therapy can play a crucial role in maintaining mobility and reducing pain. […] Support groups and counseling services can provide a platform for individuals to share experiences, seek advice, and receive emotional support from others facing similar challenges. […] Treatment includes pain management, physical therapy, and surgery in advanced cases.
#1 Podcast Extra: The quest for a rare disease treatment
https://www.nature.com/articles/d41586-019-00136-7
Nicks children, both of whom have AKU, will have access to this drug in the UK, and if these upcoming European trial results are positive, which theyre expected to be, nitisinone will hopefully be accessible to patients outside of the UK. […] What our programme has demonstrated is if you can get clinicians, basic scientists and patient societies and potentially funders as well, coming together and working collaboratively, I think you can make rapid strides as we have shown in such a small space of time because we only really started doing the research in 2006-2007, so in ten years we have gone from having nothing to really having a working treatment for a condition which has not had one for more than 100 years.
#2 Alkaptonuria: Causes, Symptoms, Diagnosis, and Treatment Options Explained | OnlyMyHealth
https://www.onlymyhealth.com/alkaptonuria-causes-symptoms-diagnosis-treatment-12977827239
While there is no cure for alkaptonuria, treatment can help manage symptoms and prevent complications. Some effective strategies include: […] Medication: Nitisinone, a drug that reduces homogentisic acid production, may help slow disease progression. […] Pain management: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and physical therapy can help relieve joint pain. […] Lifestyle changes: A low-protein diet may help reduce the production of homogentisic acid. […] Surgical interventions: In severe cases, joint replacement surgery may be necessary. […] Regular monitoring: Routine check-ups can help manage cardiovascular and kidney-related complications. […] Alkaptonuria is a lifelong condition that requires careful management to prevent complications and maintain quality of life. Early diagnosis and appropriate interventions, such as medication, lifestyle modifications, and regular medical check-ups, can help individuals manage the symptoms effectively.
#2 Podcast Extra: The quest for a rare disease treatment
https://www.nature.com/articles/d41586-019-00136-7
Searching for a treatment for alkaptonuria. […] Nick and his wife were very sceptical, and sought out a second opinion. A few months later, after tests were run at Great Ormond Street Hospital in the UK, the results came back. Their son had a rare genetic disease called alkaptonuria or AKU for short. […] Nick wasnt content to accept this prognosis for his son, but there was room for optimism. Across the Atlantic in the United States, Dr William Gahl at the National Institutes of Health was doing a clinical study for AKU on a drug which had been used to treat a much more severe disease called type-1 tyrosinaemia. […] This has meant that last year, Nicks oldest son got his first dose of nitisinone off license. […] With lots of positive data now from this observational study at the AKU centre, Nick and his colleagues wanted to change the lives of more people, so they turned their gaze to Europe.
#2 Ochronosis and Alkaptonuria Treatment & Management: Medical Care, Surgical Care, Consultations
https://emedicine.medscape.com/article/1104184-treatment
Ranganath et al have shown that nitisinone 2 mg daily and 10 mg daily are beneficial in patients with alkaptonuria, with 10 mg displaying a greater decrease in HGA. The authors note that a diet lower in protein would likely improve safety with the higher dose. Nitisinone 10 mg was approved by the European Medicines Agency for adults with alkaptonuria in 2020. […] Nitisinone is approved in the United States for the treatment of children with tyrosinemia type I. It acts by inhibiting the enzyme 4-hydroxyphenyl pyruvic acid and therefore can decrease formation of HGA. […] Vitamin E and N-acetyl cysteine have been examined as novel potential therapies to prevent damage to articular cartilage. […] Ochronotic arthropathy is treated with physiotherapy, analgesia, rest, and prosthetic joint replacement when necessary.
#2
https://www.liverpool.ac.uk/health-and-life-sciences/research/impact/alkaptonuria/
Researchers at the University of Liverpool developed the first effective pharmacological treatment option for the disease which transforms management and experience of the disease. Young people with alkaptonuria can now expect to live free of its debilitating symptoms whilst existing older patients are seeing symptoms arrested and some reversed. […] During a ten-year period (2009-2019), the Liverpool team worked with nitisinone, eventually proving its efficacy as a therapy for alkaptonuria, through completing an observational study and clinical trials of the therapy. Findings included that at 12 months, homogentisic acid (HGA), the cause of alkaptonuria, was decreased by 99.7%. […] Based on Liverpools trial results, pharmaceutical company Swedish Orphan Biovitrum applied to the European Medicine Agency (EMA) to license the treatment, as Orfadin. EMA granted the license with the EU market size estimated as 2,275 patients, with 30-50 new patients identified each year.
#2 Clinical development innovation in rare diseases: overcoming barriers to successful delivery of a randomised clinical trial in alkaptonuriaâa mini-review | Orphanet Journal of Rare Diseases | Full Text
https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02606-0
The SONIA 2 study end in February 2019, data analysis was completed and the main publication setting out the results of the study was published in 2020, while at the same time a compilation of documents were sent to the European Medicines Agency for label extension of NIT to cover its use in adults with AKU, also achieved in 2020. […] The participation of a pharmaceutical partner as well as an effective consortium are crucial to success.
#2 Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria | Scientific Reports
https://www.nature.com/articles/s41598-022-20424-z
Nitisinone (NIT) is approved by the European Medicines Agency as the first disease-modifying therapy for AKU. […] It decreases HGA by inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) and consequently ameliorates AKU. […] However, inhibition of HPPD also leads to accumulation of metabolites proximal to this inhibition, including TYR leading to severe tyrosinaemia which can cause unwanted effects such as corneal keratopathy, and, as more recently reported, vitiligo and cataract formation. […] Management of NIT-induced tyrosinaemia is challenging in adults due to the severely restricted diet needed affecting patients’ quality of life and optimal sTYR not being achievable without PHE/TYR-free amino acid supplements. […] In the United Kingdom National Alkaptonuria Centre, sTYR intervals are used pragmatically.
#2 Alkaptonuria Information | Mount Sinai – New York
https://www.mountsinai.org/health-library/diseases-conditions/alkaptonuria
Management of alkaptonuria has traditionally been focused on controlling symptoms. Eating a low protein diet may be helpful, but many people find this restriction difficult. Medicines, such as NSAIDs and physical therapy may help relieve joint pain. […] Clinical trials are underway for other drugs to treat this condition and to assess whether the drug nitisinone provides long-term help with this illness.
#2 What Happens in Alkaptonuria?
https://www.medicinenet.com/what_happens_in_alkaptonuria/article.htm
How is alkaptonuria treated? There is no cure for alkaptonuria. However, Nitisinone and vitamin C has shown some promise. Painkillers and lifestyle changes may help cope with the symptoms. The condition may be managed using the following methods: […] Some individuals may benefit from high doses of vitamin C. Vitamin C has been shown to slow arthritis development and reduce the buildup of the dark pigment in urine. […] Nitisinone reduces the homogentisic acid level in the body. It’s currently an experimental treatment, but research into its effectiveness is ongoing and there have been some promising results so far. […] Dietary restriction of amino acids: phenylalanine and tyrosine. Food items such as meat products, soy products, milk products, certain types of artificial sweeteners, and nuts should be avoided.
#2 Alkaptonuria and ochronosis
https://dermnetnz.org/topics/alkaptonuria-and-ochronosis
Alkaptonuria is a lifelong disease. There is no cure for the condition. If alkaptonuria is diagnosed early on in life it is reasonable for patients to have a low-protein diet. This reduces the intake of amino acids phenylalanine and tyrosine, which in turn reduces the amount of homogentisic acid produced. Although not proven, this could potentially avoid or minimise complications later in life. […] Vitamin C has been found to slow down the conversion of homogentisic acid to the polymeric deposits in cartilage and bone. A dose of up to 1g/day is recommended for older children and adults. Nitisinone, an enzyme inhibitor that mediates the formation of homogentisic acid is being used in restricted experimental treatments. […] Exogenous cutaneous ochronosis has been successfully treated by laser.
#2
https://link.springer.com/article/10.1007/s10545-015-9888-7
In addition, safety of long-term anti-oxidant approaches has been questioned (Vivekananthan et al 2003). […] Genovese et al (2015) have for the first time shown that there are reliable biomarker changes in AKU that can inform on the stage of the disease and its progression. […] It is still not known when ochronosis begins or takes hold and studies of biomarkers may allow us to answer this question.
#2 Alkaptonuria (Black Urine Disease) – Causes, Symptoms, Diagnosis, Treatment and Prognosis
https://www.medindia.net/health/conditions/alkaptonuria.htm
Dietary restriction of protein may help in reducing the intake of phenylalanine and tyrosine, thereby slowing the progression of the disease by reducing the production of HGA. […] Painkillers and anti-inflammatory agents such as paracetamol, ibuprofen and naproxen can help to relieve pain and swelling. Procedures like transcutaneous electrical nerve stimulation (TENS) can help in appreciably reducing pain by numbing the nerve endings of the spinal cord. […] Surgical intervention may be necessary if joint replacement or heart valve replacement is required.
#2 Azthena logo with the word Azthena
https://www.news-medical.net/health/What-is-Alkaptonuria.aspx
Alkaptonuria is diagnosed by detecting HGA in urine using gas chromatography-mass spectrometry, and is confirmed by genetic testing to identify a recessive mutation on the HGD gene. […] Management is symptomatic and may include: […] Palliation of joint pain […] Physical therapy to strengthen the muscles and maintain flexibility […] Occupational therapy to help the patient remain independent and carry out activities of daily living […] Joint replacements when needed […] Treatment of renal and prostate calculi […] Aortic valve replacement if required. […] Regular monitoring is necessary to identify the presence of aortic dilatation, valve disease, and coronary calcification. This may require various imaging techniques. Joint stress, such as high-impact sports or heavy manual work should be avoided. Family screening and early intervention may help reduce or prevent complications in other relatives.
#2 Alkaptonuria: Causes, Symptoms, and Treatment Methods | DocHospitals
https://dochospitals.com/en/alkaptonuria-atc1324/
Although there is no definitive treatment method for alkaptonuria, treatment is usually aimed at reducing the patient’s symptoms. Medications and changes in the patient’s lifestyle aim to reduce the symptoms of the disease. […] In alkaptonuria, drugs with the active substance nitisinone are preferred medically. There are ongoing studies showing that nitisinone reduces the level of homogentisic acid in the body. […] For people with involvement of the joints and spine, relief is provided with painkillers. In advanced cases, joint replacement can be performed with surgical operations. […] Physiotherapy support to strengthen muscles and joints improves the patient’s quality of life. […] Regular light exercise helps to reduce the pain of the disease. Activities that reduce stress levels such as yoga, pilates, cycling and walking can be preferred. […] Surgery may be necessary in patients with involvement of heart valves or heart vessels. […] The use of vitamin C slows down calcification in some patients and reduces the dark color of urine. […] Reduce consumption of foods rich in tyrosine and phenylalanine, such as milk, meat and eggs.
#2 Ochronosis and Alkaptonuria Treatment & Management: Medical Care, Surgical Care, Consultations
https://emedicine.medscape.com/article/1104184-treatment
Arthroscopy has been found to be effective in alleviating joint pain and improving mobility in cases of ochronotic arthropathy. […] Knee, hip, shoulder, and other joint replacements may be needed if ochronotic arthropathy progresses substantially. Surgical intervention for prostate and renal stones may also be necessary. Aortic valve replacement is indicated in the case of aortic calcification and stenosis. […] Surgical replacement of cardiac valves may be necessary in cases of ochronosis.
#2 Alkaptonuria Disease: Symptoms, Causes and Treatment
https://tap.health/how-to-diagnose-alkaptonuria-urine-analysis-and-genetic-testing/
Research into potential gene therapies and pharmacological interventions for Alkaptonuria is ongoing, with the aim of developing targeted treatments that address the underlying genetic mutations responsible for the condition. Clinical trials and studies are essential in advancing our understanding of Alkaptonuria and exploring novel therapeutic approaches.
#2
https://link.springer.com/article/10.1007/s10545-015-9888-7
Alkaptonuria (AKU, MIM#203500), an iconic disease, has the distinction of being the disorder leading to the creation and evolution of the inherited metabolic disease branch of medicine (Garrod 1908). […] Attempts to treat alkaptonuria by use of genetic engineering to replace the missing enzyme no doubt will be made soon. […] Recent progress has brought us to the stage of posing another question Are we near to an effective therapy for Alkaptonuria? […] It is notable that three of these papers are focussed on the potential of nitisinone in treating the disease. Nitisinone, a p-hyodroxyphenyl pyruvate dioxygenase inhibitor, is not approved for AKU, although it has been used in a life-threatening disease hereditary tyrosinaemia type 1 for more than 20 years with great success. […] Despite the inconclusive results of the first trials of nitisinone in AKU (Introne et al 2011), the drug has been shown to be completely effective in inhibiting ochronosis in AKU mice (Preston et al 2014) and at lowering circulating HGA in AKU patients (Ranganath et al 2014).
#2 Redefining a new frontier in alkaptonuria therapy with AI-driven drug candidate design via in-silico innovation
https://www.degruyter.com/document/doi/10.1515/znc-2024-0075/html?lang=en
However, because nitisinone use has resulted in acquired tyrosinosis, increased liver transaminases, and corneal crystals, the FDA has not approved its use to treat alkaptonuria. […] This study utilized the natural flavonol kaempferol as a 4-hydroxyphenylpyruvate dioxygenase inhibitor to address the toxicity issues associated with the AKU medication nitisinone. […] Therefore, it is important to optimize its therapeutic potential for a more effective treatment of alkaptonuria. […] Consequently, for the treatment of the patients, a drug designed specifically for alkaptonuria with few adverse effects is a dire need. […] The AI technology employed with kaempferol developed three effective de novo drug compounds that were effective against the 4-hydroxyphenylpyruvate dioxygenase enzyme.
#2 Ochronosis – Alkaptonuria and Exogenous – Dermatology Advisor
https://www.dermatologyadvisor.com/home/decision-support-in-medicine/dermatology/ochronosis-alkaptonuria-and-exogenous/
Large doses of vitamin C (1g/day) could be used to prevent the deposition of ochronotic pigment. […] Other antioxidants such as N-acetyl cystein and Vitamin E can be added to medical therapy; they have been shown to reduce HGA polymerization and in vitro accumulation. […] Use of nitisinone, an inhibitor of the enzyme that forms HGA (i.e., para-hydroxyphenylpyruvic acid dioxygenase), lowers HGA production. […] Nitisinone has also been shown to reduce urinary excretion of HGA. […] The dosage in adults is 0.35mg per oral, twice a day. […] As the gene responsible for alkaptonuria has been identified, replacement therapy with recombinant enzyme could be a new approach in the treatment of the disease. […] Genetic counseling should be offered. […] Treatment of exogenous ochronosis requires that the patient stop using the responsible agent immediately. […] Retinoic acid plus sunscreens, dermabrasion, or carbon dioxide laser can be tried, but treatment has varying degrees of success.
#2 Alkaptonuria: Symptoms, Causes, Treatment
https://www.medicoverhospitals.in/diseases/alkaptonuria/
Routine check-ups with healthcare providers are essential to monitor the progression of the disease and adjust treatment plans as needed. […] Physical therapy can play a crucial role in maintaining mobility and reducing pain. […] Support groups and counseling services can provide a platform for individuals to share experiences, seek advice, and receive emotional support from others facing similar challenges. […] Treatment includes pain management, physical therapy, and surgery in advanced cases.
#2 Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria | Scientific Reports
https://www.nature.com/articles/s41598-022-20424-z
Protein intake is reduced to 0.9 and 0.8 g/kg body weight for sTYR values between 501-700, and 701-900 mol/L respectively, whereas in those with values greater than 900 mol/L, additional PHE/TYR free amino acid supplements are also employed. […] The decrease in conversion of PHE to TYR during NIT-induced tyrosinaemia seems to be an adaptive response to minimise TYR formation. […] A better understanding of the adaptive response to NIT therapy may possibly translate into a tool to predict keratopathy in the future. […] The contributions of dietary protein intake and the magnitude of rise in circulating NIT seem to be less influential than decreased conversion of HPPA to HPLA in determining the degree of tyrosinaemia during NIT treatment in SONIA 2.
#2 Alkaptonuria Disease: Symptoms, Causes and Treatment
https://tap.health/how-to-diagnose-alkaptonuria-urine-analysis-and-genetic-testing/
Currently, there is no cure for Alkaptonuria. However, various treatment options aim to alleviate symptoms and improve the quality of life for individuals with this condition. […] The management of joint pain and stiffness often involves a multidisciplinary approach. Healthcare professionals may prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) and recommend physical therapy to help patients alleviate discomfort and maintain joint mobility. In severe cases, joint replacement surgery may be necessary to restore function and relieve pain. […] Additionally, diet modifications may be suggested to minimize the intake of tyrosine and phenylalanine, which are precursors of HGA. To carefully balance dietary restrictions, one must ensure adequate nutrient intake. […] Furthermore, individuals with Alkaptonuria may benefit from regular monitoring and follow-up care to track the progression of the disease and adjust treatment strategies accordingly. This may involve frequent visits to healthcare providers, including genetic counselors, rheumatologists, and orthopedic surgeons, to address specific aspects of the condition.
#3 Redefining a new frontier in alkaptonuria therapy with AI-driven drug candidate design via in-silico innovation
https://www.degruyter.com/document/doi/10.1515/znc-2024-0075/html?lang=en
The assessment of AIK toxicity with a machine learning embedded toxicity tool suggests a potentially lower predicted toxicity profile, highlighting the need for further in vitro and in vivo studies for definitive safety assessment. […] This study employed computational methods to identify potential therapeutic inhibitors for alkaptonuria. […] Future in-vitro and in vivo trials can be performed to validate the authenticity and accuracy of the evaluated predictions of this study. […] AIK, designed by AI assistance, was found by this computational study to be a strong inhibitor of 4-hydroxyphenylpyruvate dioxygenase in compliance with the Lipinski rule of five, suggesting promising drug-like characteristics. […] Additionally, AIK showed an ADMET profile that was non-toxic, indicating that it is a safer option than nitisinone. […] These findings support AIKs experimental validation and may provide a safer and more effective alkaptonuria treatment.